On August 16, 2022, Titan Pharmaceuticals, Inc announced that at its annual general meeting of shareholders held on August 15, 2022, the stockholders elected all of David E Lazar's 6 nominees: Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo, and David Natan for director to serve until the next annual meeting of stockholders and until their successors are elected and are qualified.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.09 USD | +1.72% | -3.14% | -14.06% |
Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
1st Jan change | Capi. | |
---|---|---|
-14.06% | 6.48M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Declaration of Voting Results by Titan Pharmaceuticals, Inc